NCT04058678 is a NA clinical trial of Without intervention in Ovarian Reserve, sponsored by IVI Madrid.

Who is sponsoring NCT04058678?

NCT04058678 is sponsored by IVI Madrid.

What drugs are being tested in NCT04058678?

Interventions in NCT04058678: Danazol/Placebo, Without intervention.

What condition does NCT04058678 study?

NCT04058678 studies Ovarian Reserve.

Is NCT04058678 still recruiting?

NCT04058678 is currently completed. Last updated 10 August 2022.

Last reviewed 2022-08-10 · How we verify

NCT04058678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Telomerase Reactivation With Danazol in Ovarian Function.

Completed NA Last updated 10 August 2022

What this trial tests

NA trial testing Danazol/Placebo in Ovarian Reserve in 19 participants. Completed in 31 December 2021.

Timeline

30 January 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	IVI Madrid
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	19
Start date	30 January 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Spain

Drugs / interventions tested

Danazol/Placebo — full drug profile →
Without intervention

Conditions studied

Ovarian Reserve — all drugs for Ovarian Reserve →

Sponsor

IVI Madrid — full company profile →

Who can join

Adults 30 to 45, female only, with Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project explores the implication of the telomere pathway in ovarian premature and regular aging. Telomere length and maintenance underlie several biological processes such cancer, aging, human diseases and the biology of stem cells. The reactivation of telomerase should lead to a rejuvenation of the ovarian tissue and the improvement of fertility. The correlation of telomeric factors in blood and granulosa cells will be studied with the aim of finding telomeric biomarkers of ovarian aging.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Without intervention

Trials testing the same drug.

NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
NCT06065618 — Characteristics of Hospitalized Patients With Community-acquired Pneumonia · unknown
NCT03882515 — Evaluation Of Peripheral Muscle Oxygenation In Individuals With Muscular Idiopathic Pain With Myofascial Release · NA · completed

Other recruiting trials for Ovarian Reserve

Currently open trials in the same condition.

NCT07469007 — Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO) · NA · recruiting
NCT06626282 — Fertility and Ovarian Reserve in Female Childhood Cancer Survivors · recruiting
NCT06633120 — In Vitro Maturation of Human Eggs · NA · recruiting
NCT04487925 — Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders · Phase 4 · recruiting

Other IVI Madrid trials

Trials by the same sponsor.

NCT06244745 — Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. · Phase 3 · recruiting
NCT05606679 — Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. · unknown
NCT05508217 — Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development · unknown
NCT02718105 — Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate · completed
NCT04778358 — Higher Dose of Rekovelle in Oocyte Donors · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04058678 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IVI Madrid
Last refreshed: 10 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04058678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing